The relationship between cognitive-motor impulsivity, dopaminergic genotype and dopamine agonist medication in healthy individuals

Professor Winston Byblow0 sites33 target enrollmentJanuary 17, 2014

Overview

Phase: Phase 1
Intervention: Not specified
Conditions: Impulse control disorders in Parkinson's disease patients taking dopaminergic medication
Sponsor: Professor Winston Byblow
Enrollment: 33
Status: Completed
Last Updated: 5 years ago

No summary available.

Registry

who.int

Start Date

January 17, 2014

End Date

December 31, 2015

Last Updated

5 years ago

Study Type

Interventional

Sex

All

Sponsor

Professor Winston Byblow

•Cognitive impairment (MoCA score below 26\); unable to provide informed consent; any contraindications to the medications or placebo. Contraindications include: a known hypersensitivity to ropinirole, domperidone, or any of the excipients; history of acute or chronic psychiatric disorder; history of severe cardiac, hepatic or renal disease; history of severe systemic disease; history of severe dizziness or fainting; a prolactin\-releasing pituitary tumour; currently breast feeding; current tobacco smoking or nicotine patch; lactose intolerance; glucose/galactose malabsorption and any medications which may interact with ropinirole or domperidone, or themselves cause drowsiness.